Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464514 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL1012066 | 0.86 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL3656139 | 0.86 | ALDH1A1 (0.47) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL5730907 | 0.86 | OPRM1 (0.40) | OPRL1OPRM1HTR3EHTR3BCHRNA7 | |
| SCHEMBL7568500 | 0.86 | CYP2D6 (0.48) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL11173935 | 0.84 | OPRL1 (0.60) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL11173936 | 0.84 | OPRL1 (0.60) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL7157429 | 0.84 | OPRK1 (0.46) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL4591523 | 0.84 | OPRM1 (0.47) | SLC6A4SLC6A3OPRL1OPRM1 | |
| SCHEMBL8347022 | 0.83 | HRH3 (0.37) | SLC6A2SLC6A4SLC6A3OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| US-11766429-B1 | Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19 | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-09-26 | — | — | US | disclosed |
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-1011678-B1 | USE OF MECAMYLAMINE FOR THE TREATMENT OF NICOTINE-RESPONSIVE NEUROPSYCHIATRIC DISORDERS | UNIV SOUTH FLORIDA (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1699488-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | Pfizer Products Incorporated (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6979698-B1 | Method of treating cognitive deficits in learning and memory | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005063296-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1011678-A4 | NICOTINE ANTAGONISTS FOR NICOTINE-RESPONSIVE NEUROPSYCHIATRIC DISORDERS | UNIV SOUTH FLORIDA (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6537522-B1 | Metabolically stable cocaine analogs such as 2-carbometh-oxy-3-(4-iodophenyl)-tropane; chemical intermediates for compounds having high affinities for dopamine and serotonin reuptake sites in brain | AMERSHAM PLC (GB) | 2003-03-25 | — | — | US | disclosed |
| WO-1999007378-A1 | NICOTINE ANTAGONISTS FOR NICOTINE-RESPONSIVE NEUROPSYCHIATRIC DISORDERS | THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5750089-A | Halogenated neuroprobe for mapping monoamine reuptake sites | NEURO IMAGING TECHNOLOGIES, LLC (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0831941-A1 | IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES | Research Biochemicals, Limited Paternership, doing business as Research biochemicals International (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5698179-A | Iodinated neuroprobe for mapping monoamine reuptake sites | NEURO IMAGING TECHNOLOGIES, LLC (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1996039198-A1 | IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOCHEMICALS, LIMITED PARTNERSHIP, doing business as RESEARCH BIOCHEMICALS INTERNATIONAL, A MASSACHUSETTS LIMITED PARTNERSHIP, WHOSE SOLE GENERAL PARTNER IS RBI MANAGEMENT, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0703791-A4 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RES BIOMED LP (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0703791-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOMEDICALS LIMITED PARTNERSHIP (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5439666-A | Central nervous system | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1995001184-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-01-12 | — | — | WO | disclosed |
| US-5310912-A | Ester-substituted nortropane | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1994-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | CHRNA3, CHRNA7, CHRNA2 | SLC6A2 131/4885SLC6A4 172/4885SLC6A3 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.